A granular Lyme Disease Diagnostic Market region analysis shows that North America currently leads the global market with an industry share exceeding 48%. The United States, in particular, serves as the primary hub for innovation, supported by the CDC’s increased focus on tick-borne disease surveillance and high consumer demand in the Northeast and Midwest. Canadian markets are also expanding as warmer winters allow deer ticks to migrate further north into previously unaffected provinces, necessitating new regional diagnostic infrastructure.

Europe represents the second-largest market, with Central Europe (specifically Germany, Austria, and Poland) reporting the highest infection rates in the region. European market leaders are focusing on specialized immunoblot assays that can distinguish between various Borrelia species unique to the continent, such as B. garinii and B. afzelii. Meanwhile, the Asia-Pacific region is poised for high growth, driven by improved diagnostic access in rural China and Japan and a burgeoning middle class that is increasingly seeking Western-standard medical diagnostics for fever-related illnesses.

Related Reports